# Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. is a Publicly Traded Biopharmaceutical Company based in Cranbury, United States.

## Overview

- **Organization type:** Publicly Traded Biopharmaceutical Company
- **Headquarters:** Cranbury, United States
- **Region:** North America
- **Address:** Cranbury, NJ, United States
- **Founded:** 2019
- **Assets under management:** Undisclosed
- **Website:** outlooktherapeutics.com
- **LinkedIn:** https://www.linkedin.com/company/outlook-therapeutics

## Regulatory record

- **Reports private funds:** No

## About

Outlook Therapeutics, Inc. was founded in 2019 through a merger with Diffusion Pharmaceuticals Inc., emerging as a standalone ophthalmology-focused biotech. The company is led by CEO Jeffrey Evans, with Lawrence Kenyon as CFO and Rogério Vivaldi Coelho as Chief Medical Officer. Its primary asset is ONS-5010 (LYTENAVA), an investigational anti-VEGF biologic for retinal diseases (per SEC filings, 2023). The company's strategy centers on regulatory approval and commercialization of ONS-5010, targeting wet age-related macular degeneration, diabetic macular edema, and other retinal disorders. It conducts clinical trials across the US, Europe, and Latin America. Manufacturing partnerships and potential co-commercialization agreements form part of its capital-light model (per company filings, 2023). As a publicly traded firm (NASDAQ: OTLK), Outlook Therapeutics does not disclose assets under management. It reported a net loss of $35.2 million for fiscal year 2023, with cash reserves of $17.3 million as of September 30, 2023 (per SEC filing). No office expansion or financings exceeding $100 million have been publicly announced in the last 24 months. Outlook Therapeutics' structural differentiator is its focus on a single lead program — a high-risk, high-reward strategy typical of pre-commercial biotechs. The company relies on regulatory milestones rather than diversified pipelines, making its posture binary relative to larger pharmaceutical firms. Its public-company governance structure differs from traditional family offices or private equity.

## Sectors

- Biotech
- Ophthalmology
- Therapeutics

## People

- Jeffrey Evans — Chief Executive Officer
- Lawrence Kenyon — Chief Financial Officer
- Rogério Vivaldi Coelho — Chief Medical Officer

## Questions

### Who manages investment decisions at Outlook Therapeutics?

Outlook Therapeutics is a publicly traded biopharmaceutical company (NASDAQ: OTLK) led by CEO Jeffrey Evans. Strategic decisions are made by the board of directors, which includes independent directors, and subject to shareholder approval (per SEC filings, 2023).

### What is Outlook Therapeutics' lead product candidate?

The company's lead candidate is ONS-5010 (LYTENAVA), an anti-VEGF biologic for wet age-related macular degeneration. It is in late-stage clinical development in the US and Europe (per company press releases, 2023).

### Does Outlook Therapeutics participate in direct investments or fund commitments?

Outlook Therapeutics is not an investment firm. It operates as a biotech developer, funding its operations through public equity offerings, debt, and grant funding (per SEC filings, 2023).

### Which sectors does Outlook Therapeutics focus on?

The company focuses exclusively on ophthalmology and retinal disease therapeutics. It avoids other therapeutic areas or investment sectors (per company filings).

### How is Outlook Therapeutics related to Diffusion Pharmaceuticals?

Outlook Therapeutics was formed in 2019 via a reverse merger with Diffusion Pharmaceuticals Inc., which had been focused on cancer therapies. Post-merger, the combined entity pivoted to ophthalmology (per SEC filings, 2019).

### What is the company's geographic footprint?

Outlook Therapeutics is headquartered in Cranbury, New Jersey, and conducts clinical trials in the US, Europe, and Latin America. It does not operate investment offices globally (per company filings).

## Related profiles

- [Vanguard Green Investment Ltd](https://altss.com/profile/vanguard-green-investment-ltd)
- [BayFirst Financial Corp.](https://altss.com/profile/bayfirst-financial-corp)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/outlook-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology